Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialByeong-Ho Park, David H. Kirn, Jae‐Seok Kim et al.|The Lancet Oncology|2008Cited by 522